U.S. Interactive Media and Services Stock News

NYSE:MSGS
NYSE:MSGSEntertainment

A Look At Madison Square Garden Sports (MSGS) Valuation After Proposed Knicks And Rangers Spin Off

Madison Square Garden Sports (MSGS) has drawn fresh attention after its board unanimously approved exploring a spin off that would separate the New York Knicks and New York Rangers into two independent, publicly traded companies. See our latest analysis for Madison Square Garden Sports. That spin off announcement and the CFO transition come after a strong run in the share price, with Madison Square Garden Sports posting a 90 day share price return of 48.11% and a 1 year total shareholder...
NasdaqGS:MRX
NasdaqGS:MRXCapital Markets

Assessing Marex Group (NasdaqGS:MRX) Valuation After Recent Share Price Momentum

Marex Group (MRX) has drawn fresh attention after recent share price moves, with the stock showing double digit returns over the month and past 3 months. This has prompted investors to reassess the diversified financial services platform. See our latest analysis for Marex Group. The recent rally sits on top of a broader upswing, with a 30 day share price return of 10.97% and year to date share price return of 15.47%. The 1 year total shareholder return of 23.13% points to building momentum as...
NasdaqGS:OTEX
NasdaqGS:OTEXSoftware

OpenText’s Expanded Buyback and Vertica Sale Could Be A Game Changer For Open Text (OTEX)

OpenText recently expanded its FY26 share repurchase program by US$200 million to US$500 million and approved buying back up to 24,906,456 shares for cancellation, while also selling its Vertica analytics database business to Rocket Software for US$150 million. Together, the larger buyback and Vertica divestiture highlight a shift toward returning more capital to shareholders while sharpening the company’s focus on core information management offerings. We’ll now examine how the expanded...
NasdaqCM:NEO
NasdaqCM:NEOHealthcare

A Look At NeoGenomics (NEO) Valuation After The RaDaR ST Assay Launch

NeoGenomics (NEO) has drawn fresh attention after launching RaDaR ST, a circulating tumor DNA assay designed to detect molecular residual disease in blood using patient specific panels and advanced bioinformatics. See our latest analysis for NeoGenomics. Despite the RaDaR ST launch and recent earnings and guidance updates, NeoGenomics' 30 day share price return of 21.23% and year to date share price return of 19.22% both point to fading near term momentum. At the same time, the 5 year total...
NasdaqGM:RDNT
NasdaqGM:RDNTHealthcare

RadNet (RDNT) Q4 Loss On US$547.7m Revenue Tests Margin Expansion Narrative

RadNet (RDNT) closed out FY 2025 with Q4 revenue of US$547.7 million and basic EPS of roughly US$0.01 loss, while trailing twelve month figures show revenue at about US$2.0 billion and basic EPS of roughly US$0.25 loss. The company has seen quarterly revenue move from US$471.4 million in Q1 2025 to US$547.7 million in Q4 2025, with basic EPS swinging between a US$0.51 loss and US$0.19 profit over the same span. This sets up a story that focuses on how quickly margins can stabilize from...
NasdaqGS:LIN
NasdaqGS:LINChemicals

A Look At Linde (LIN) Valuation As Rising Natural Gas Costs Pressure Margins

Linde (LIN) is back in focus as the stock reacts to rising natural gas costs tied to Middle East tensions and the closure of the Strait of Hormuz, a key route for global energy supplies. See our latest analysis for Linde. Beyond the immediate reaction to energy cost concerns, Linde’s share price has shown strong momentum, with an 11.46% 30 day share price return and an 18.70% year to date share price return. Over a longer horizon, the 1 year total shareholder return of 11.67% and 5 year total...
NasdaqGM:TRUP
NasdaqGM:TRUPInsurance

Trupanion’s Return To Profitability And Pricing Shift Might Change The Case For Investing In TRUP

In late February 2026, Trupanion reported its full-year 2025 results, highlighting a return to profitability with net income of US$19.4 million and surpassing US$1.00 billion in annual subscription revenue driven by pricing aligned to rising veterinary costs and improved operating margins. The company also issued an optimistic 2026 outlook, projecting total revenue of about US$1.55–US$1.58 billion and targeting adjusted operating income growth of roughly 19%, while exploring lower-priced...
NYSE:XOM
NYSE:XOMOil and Gas

Did Middle East Tensions and a Board Change Just Shift Exxon Mobil's (XOM) Investment Narrative?

In recent days, escalating conflict involving Iran and effective disruption around the Strait of Hormuz have pushed global oil prices sharply higher, focusing attention on Exxon Mobil’s large upstream operations. At the same time, Exxon Mobil confirmed that director Jeffrey W. Ubben will not seek re-election at the May 2026 shareholder meeting, though his departure is described as unrelated to the company. These developments highlight how sudden geopolitical supply risks can reinforce the...
NYSE:SR
NYSE:SRGas Utilities

A Look At Spire (SR) Valuation After Preferred Stock Termination And Recent Earnings And Dividend Updates

Spire (SR) has drawn fresh attention after terminating the certificate of designations for its 5.90% Series A Cumulative Redeemable Perpetual Preferred Stock, along with recent earnings and dividend updates in the natural gas utilities sector. See our latest analysis for Spire. That change to Spire’s capital structure comes as the share price trades at US$91.66, with a 30 day share price return of 8.49% and a 1 year total shareholder return of 22.45%. The 5 year total shareholder return of...
NYSE:PFE
NYSE:PFEPharmaceuticals

Does New Oncology Data Shift The Pipeline-Driven Bull Case For Pfizer (PFE)?

In late February 2026, Pfizer and Astellas reported that PADCEV plus Keytruda cut the risk of tumor recurrence, progression or death in cisplatin-eligible muscle-invasive bladder cancer patients versus standard chemotherapy, while Pfizer also secured full FDA approval for BRAFTOVI-based combination therapy in first-line BRAF V600E-mutant metastatic colorectal cancer. Together, these oncology advances strengthen Pfizer’s presence in high-need cancer settings and may help offset pressure from...
NYSE:RRC
NYSE:RRCOil and Gas

Assessing Range Resources (RRC) Valuation After Record 2025 Results And Higher Dividend

Range Resources (RRC) is back in focus after reporting 2025 results with record operational efficiencies, setting a new 2026 capital plan and production guidance, and lifting its quarterly dividend payout to shareholders. See our latest analysis for Range Resources. The recent earnings beat, operational records and dividend increase appear to be feeding into solid momentum, with a 7 day share price return of 8.6% and a year to date share price return of 18.6%, while the 5 year total...
NYSE:BIO
NYSE:BIOLife Sciences

Assessing Bio-Rad (BIO) Valuation After Mixed Share Price Performance And Recurring Revenue Shift

Bio-Rad Laboratories (BIO) has been drawing attention after a mixed stretch for the share price, with gains over the past year but declines over the past 3 months and year to date. See our latest analysis for Bio-Rad Laboratories. Recent trading has been choppy, with a 4.23% 7 day share price return following a weaker 30 day share price return of a 4.80% decline. A 12.23% decline over 90 days points to fading momentum despite a 9.02% 1 year total shareholder return. If this mixed performance...
NYSE:MMS
NYSE:MMSProfessional Services

Assessing Maximus (MMS) Valuation After Recent Share Price Weakness

Event context and recent share performance Maximus (MMS) has come onto investors’ radar after a period of mixed share performance. The stock is down roughly 22% over the past month and about 15% over the past 3 months. See our latest analysis for Maximus. Against this recent slide, Maximus still has a 1 year total shareholder return of 16.64%. However, the 3 year and 5 year total shareholder returns of 6.02% and 6.59% declines suggest fading longer term momentum. If Maximus’ move has you...
NYSE:CAG
NYSE:CAGFood

Conagra Board Refresh Brings Retail And Foodservice Focus To Undervalued Stock

Conagra Brands (NYSE:CAG) has added John Mulligan and Pietro Satriano to its board of directors. Mulligan and Satriano bring leadership experience from Target, McDonald's, US Foods, and Loblaw. The appointments signal a focus on retail operations, finance, and foodservice expertise at the board level. Conagra Brands, trading at $19.18, sits in a challenging spot after a 20.8% decline over the past year and a 33.5% decline over five years, even with a 10.9% gain year to date. For investors...
NYSE:CSR
NYSE:CSRResidential REITs

The Bull Case For Centerspace (CSR) Could Change Following 2026 Loss Guidance After 2025 Profitability

In February 2026, Centerspace reported fourth-quarter 2025 results showing sales of US$66.62 million and a net loss of US$18.38 million, alongside full-year sales of US$273.66 million and net income of US$17.59 million. The company paired this with 2026 guidance calling for a diluted net loss per share of US$0.49 to US$0.19, signaling a potential step back after returning to profitability in 2025. Next, we’ll examine how Centerspace’s return to profit in 2025 but projected loss in 2026...
NYSE:IRM
NYSE:IRMSpecialized REITs

Will Falling Short Interest Signal a Deeper Shift in Iron Mountain's (IRM) Investor Confidence?

In recent weeks, Iron Mountain Inc. has seen its short interest fall by 14.69%, with 3.6% of its freely traded shares now sold short, below the peer average of 5.54%. This pullback in bearish positioning suggests a meaningful shift in sentiment, as investors appear relatively more confident in Iron Mountain’s outlook than in many of its peers. With this backdrop of easing short interest, we’ll explore how changing investor sentiment could influence Iron Mountain’s evolving investment...
NasdaqGS:MORN
NasdaqGS:MORNCapital Markets

Is Morningstar (MORN) Quietly Redefining Its Edge Through Retirement Platforms And Data Integration?

Morningstar, Inc. has appointed Scott Brown as President, Direct Platform, effective March 2, 2026, and Morningstar Retirement has launched the Foundation Series multi-manager Collective Investment Trusts in collaboration with Alta Trust Company and nine asset managers to expand access to institutional-quality solutions for retirement plans. Together with recent research and coverage underscoring Morningstar’s role in retirement income guidance and its expanding data and platform...
NYSE:HLX
NYSE:HLXEnergy Services

Is Helix’s 2025 Earnings Miss and Impairment Reshaping the Investment Case For Helix (HLX)?

Helix Energy Solutions Group, Inc. recently reported fourth-quarter and full-year 2025 results showing lower sales and net income year-on-year, alongside a US$18,064,000 long-lived asset impairment and completion of a US$71.49 million share repurchase program that retired 9,094,398 shares since February 2023. As the company now evaluates acquisition opportunities and broader capital deployment, investors may weigh the tension between weaker recent performance and management’s appetite for...
NYSE:CI
NYSE:CIHealthcare

Is It Time To Reassess Cigna Group (CI) After Recent Share Price Stability?

Wondering whether Cigna Group is offering good value at around US$290.85 a share, or if the market is pricing it about right? This article walks through the key valuation angles you will want to consider. The stock has recently been steady to positive, with returns of 2.7% over the past 7 days, 6.1% over the past 30 days and 4.2% year to date, set against a 4.7% decline over the past year and longer term returns of 6.5% over 3 years and 34.8% over 5 years. These moves sit alongside ongoing...
NYSE:CMRE
NYSE:CMREShipping

Costamare (CMRE) Is Up 6.8% After Profit Rises Despite Lower Revenue - Has The Bull Case Changed?

In February 2026, Costamare Inc. reported that fourth-quarter 2025 revenue was US$211.97 million versus US$224.01 million a year earlier, with net income rising to US$80.46 million from US$28.86 million and full-year 2025 net income increasing to US$364.58 million on revenue of US$877.90 million. An interesting twist is that Costamare grew quarterly and full-year net income and basic earnings per share even as both quarterly and annual revenue edged lower year on year. We will now examine...
NYSE:LEN
NYSE:LENConsumer Durables

Lennar (LEN) Valuation In Focus As Governance Activism Puts Dual Class Structure Under Scrutiny

Lennar (LEN) is back in focus after investor activism around its dual class structure, with new proposals on equal voting rights and share class level vote disclosure drawing attention ahead of the April 8 shareholder meeting. See our latest analysis for Lennar. The governance debate is landing at a time when Lennar’s share price has been more volatile, with a 1 day share price return of a 3.28% decline, a 90 day share price return of a 14.74% decline and a 3 year total shareholder return of...
NYSE:RAL
NYSE:RALElectronic

Irenic Pushes Ralliant On Costs Capital Use And Share Buybacks

Irenic Capital Management has built an activist position in Ralliant (NYSE:RAL). The fund is urging cost cuts, a sharper focus on core businesses, and changes to capital allocation. Concerns include Ralliant’s recent cost levels and a recorded goodwill impairment. Irenic is also calling for faster share buybacks as part of its proposals. Ralliant, listed on the NYSE under ticker RAL, operates as a diversified business with exposure to several core segments that are tied to long term...
NYSE:AN
NYSE:ANSpecialty Retail

Is It Time To Reassess AutoNation (AN) After Recent Share Price Pullback?

If you are wondering whether AutoNation's current share price offers real value or has already run too far, this article will walk through what the numbers actually suggest. The stock recently closed at US$193.04, with returns of 10.1% over 1 year, 38.9% over 3 years and 114.7% over 5 years. However, the most recent 7 day, 30 day and year to date returns show declines of 1.9%, 5.8% and 6.5% respectively. Recent headlines have focused on AutoNation's positioning as a large US auto retailer...
NasdaqGS:NXST
NasdaqGS:NXSTMedia

Why Nexstar Media Group (NXST) Is Up 7.2% After Beating Q4 Estimates And Reaffirming TEGNA Deal

Nexstar Media Group, Inc. has already reported Q4 and full-year 2025 results, with Q4 sales of US$1,289 million versus US$1,488 million a year earlier and a Q4 net loss of US$166 million compared with prior net income of US$241 million, while full-year 2025 sales fell to US$4.95 billion and net income to US$109 million. Despite weaker year-on-year figures, the company surpassed analyst expectations for Q4 earnings and revenue, trimmed losses at The CW, and reaffirmed plans to close its...